Drug Mingkangde 13 board market value of more than 100 billion

Drug Mingkangde 24 again rose and stopped, the stock has been 13 consecutive days of ups and downs (including the first day of 44% rise), as of the release, the stock did not open the rise and stop, at 97.60 yuan. As the first new "unicorn", drug Mingkangde sealed the listing after the 13th board, according to the issue price of 21.6 yuan, one of the signed profits have reached 76,000 yuan, breaking the previous record set by Vogue Photoelectrcon for the year's most profitable new shares, the new stock After the listing of 8 consecutive one-word board, based on the average daily price of the opening plate, each sign profit of about 58,000 yuan, and the market value of pharmaceutical Mingkangde also reached 101.7 billion yuan, becoming the pharmaceutical sector after Hengrui Pharmaceuticals, Yunnan White Pharmaceuticals, Kangmei Pharmaceuticals after the market value of 100 billion "big four".
public information shows that Pharmaceutical Mingkang is currently China's largest small molecule pharmaceutical research and development services enterprises, is CRO (pharmaceutical research and development contract outsourcing services) industry leader. It was listed on the NYSE in 2007 with a market capitalisation of more than $3 billion, was privatised in August 2015 and de-listed from the NYSE on December 10 of that year, embarking on a return to A-shares. After being de-listed from the U.S. stock market, Pharmaceutical Mingkang was separately listed into three major categories: Hequan Pharmaceuticals' landing on the new three boards in April 2015; Pharmaceuticals, which was listed in Hong Kong in June 2017; and Pharmaceutical Mingkang, which added A shares. At present, the total market value of the pharmaceutical industry is 20 billion (as of May 24), the value of the drug's biological port is 80 billion (as of May 24), and the market value of the drug mingkang is 101.7 billion (as of May 24), the combined market value of the three has exceeded 200 billion. The market value has doubled tenfold in two years since U.S. stocks were de-listed.
prospectine shows that there are currently no controlling shareholders, Li Ge, Zhao Ning, Liu Xiaozhong and Zhang Zhaoxuan, the four founders of the unanimous action, jointly control the company's 34.48 percent of the voting rights.
Li Ge and Zhao Ning stayed for Peking University. With the listing of the drug Mingkangde, the couple's family grew. As of May 9, through indirect shareholdings, Li Ge and Zhao Ning's holdings in Pharmaceutical Mingkangde, Hequan Pharmaceuticals and Pharmaceutical Biology had a market value of 25.77 billion yuan, 13.441 billion yuan and 51.193 billion yuan, respectively, totalling 90.404 billion yuan (14.153 billion U.S. dollars).
it is worth mentioning that the prospectus disclosed that Pharmaceutical Mingkang had planned to issue 104 million shares, raising 5,741 million yuan, calculated to be about 55.20 yuan per share. The final offering results showed that its initial price was set at 21.60 yuan per share, and the number of issues remained unchanged, with the amount raised falling by 60% to 2,246 million yuan.
the decline in the amount of funds raised by Drug Mingkang, the issue price-earnings ratio also fell to about 22.99 times, not more than 23 times the issue price-earnings ratio of the red line, for the subsequent "unicorn" enterprises to set a benchmark for the listing. Industry insiders say the price-to-earnings ratio is well below the industry's price-to-earnings ratio over the same period, leaving plenty of room for the secondary market. (Daily Economic News)